FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Claus Scheidereit

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Co-author Network

Publications

TOP 3
Michael Hinz; Seda Çöl Arslan; Claus Scheidereit
It takes two to tango: IκBs, the multifunctional partners of NF-κB.
Hua Jing; Julia Kase; Gregor Beuster; Bernd Dörken; Jan R Dörr; Michael Grau; Michael Hummel; Sujuan Ji; Georg Lenz; Peter Lenz; Dido Lenze; Maja Milanovic; Maurice Reimann; Claus Scheidereit; Clemens A Schmitt; Soyoung Lee
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Seda Çöl Arslan; Claus Scheidereit
The prevalence of TNFα-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Claus Scheidereit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Michael Hinz; Seda Çöl Arslan; Claus Scheidereit
It takes two to tango: IκBs, the multifunctional partners of NF-κB.
Immunological reviews 2012;246(1):59-76.
2011: Hua Jing; Julia Kase; Gregor Beuster; Bernd Dörken; Jan R Dörr; Michael Grau; Michael Hummel; Sujuan Ji; Georg Lenz; Peter Lenz; Dido Lenze; Maja Milanovic; Maurice Reimann; Claus Scheidereit; Clemens A Schmitt; Soyoung Lee
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations.
Genes & development 2011;25(20):2137-46.
2011: Seda Çöl Arslan; Claus Scheidereit
The prevalence of TNFα-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay.
PloS one 2011;6(10):e26069.
2010: Michael Hinz; Michael Stilmann; Seda Çöl Arslan; Kum Kum Khanna; Gunnar Dittmar; Claus Scheidereit
A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation.
Molecular cell 2010;40(1):63-74.
2009: Armin Rehm; Ioannis Anagnostopoulos; Kerstin Gerlach; Meike Broemer; Claus Scheidereit; Korinna Jöhrens; Michael Hübler; Roland Hetzer; Harald Stein; Martin Lipp; Bernd Dörken; Uta E Höpken
Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma.
International journal of cancer. Journal international du cancer 2009;125(10):2367-74.
2009: Michael Stilmann; Michael Hinz; Seda Cöl Arslan; Anja Zimmer; Valérie Schreiber; Claus Scheidereit
A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation.
Molecular cell 2009;36(3):365-78.
2009: Yuhang Zhang; Philip Tomann; Thomas Andl; Natalie M Gallant; Joerg Huelsken; Boris Jerchow; Walter Birchmeier; Ralf Paus; Stefano Piccolo; Marja L Mikkola; Edward Morrisey; Paul A Overbeek; Claus Scheidereit; Sarah E Millar; Ruth Schmidt-Ullrich
Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction.
Developmental cell 2009;17(1):49-61.
2007: Andrea Oeckinghaus; Elmar Wegener; Verena Welteke; Uta Ferch; Seda Cöl Arslan; Jürgen Ruland; Claus Scheidereit; Daniel Krappmann
Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.
The EMBO journal 2007;26(22):4634-45.
2007: Michael Hinz; Meike Broemer; Seda Cöl Arslan; Albrecht Otto; Eva-Christina Mueller; Rudolf Dettmer; Claus Scheidereit
Signal responsiveness of IkappaB kinases is determined by Cdc37-assisted transient interaction with Hsp90.
The Journal of biological chemistry 2007;282(44):32311-9.
2007: Wilko Weichert; M Boehm; Volker Gekeler; Marcus Bahra; J Langrehr; P Neuhaus; Carsten Denkert; G Imre; C Weller; Hans-Peter Hofmann; Silvia Niesporek; J Jacob; Manfred Dietel; Claus Scheidereit; Glen Kristiansen
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.
British journal of cancer 2007;97(4):523-30.
2007: Norbert Henke; Ruth Schmidt-Ullrich; Ralf Dechend; Joon-Keun Park; Fatimunnisa Qadri; Maren Wellner; Michael Obst; Volkmar Gross; Rainer Dietz; Friedrich C Luft; Claus Scheidereit; Dominik N Muller
Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage.
Circulation research 2007;101(3):268-76.
2007: Michael Hinz; Claus Scheidereit
Striking back at the activator: how IkappaB kinase terminates antigen receptor responses.
Science's STKE : signal transduction knowledge environment 2007;2007(384):pe19.
2006: Claus Scheidereit
IkappaB kinase complexes: gateways to NF-kappaB activation and transcription.
Oncogene 2006;25(51):6685-705.
2006: Ruth Schmidt-Ullrich; Desmond J Tobin; Diana Lenhard; Pascal Schneider; Ralf Paus; Claus Scheidereit
NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth.
Development (Cambridge, England) 2006;133(6):1045-57.
2005: Stephan Mathas; Korinna Jöhrens; Stefan Joos; Andreas Lietz; Franziska Hummel; Martin Janz; Franziska Jundt; Ioannis Anagnostopoulos; Kurt Bommert; Peter Lichter; Harald Stein; Claus Scheidereit; Bernd Dörken
Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.
Blood 2005;106(13):4287-93.
2005: Felix B Mehrhof; Ruth Schmidt-Ullrich; Rainer Dietz; Claus Scheidereit
Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisited.
Circulation research 2005;96(9):958-64.
2005: Christian Freund; Ruth Schmidt-Ullrich; Anthony Baurand; Sandra Dunger; Wolfgang Schneider; Peter Loser; Amina El Jamali; Rainer Dietz; Claus Scheidereit; Martin W Bergmann
Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo.
Circulation 2005;111(18):2319-25.
2005: Birgit Salanova; Mira Choi; Susanne Rolle; Maren Wellner; Claus Scheidereit; Friedrich C Luft; Ralph Kettritz
The effect of fever-like temperatures on neutrophil signaling.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(7):816-8.
2005: Daniel Krappmann; Claus Scheidereit
A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways.
EMBO reports 2005;6(4):321-6.
2004: Meike Broemer; Daniel Krappmann; Claus Scheidereit
Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation.
Oncogene 2004;23(31):5378-86.
2004: Daniel Krappmann; Elmar Wegener; Yoshiaki Sunami; Meral Esen; Andreas Thiel; Benjamin Mordmuller; Claus Scheidereit
The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1.
Molecular and cellular biology 2004;24(14):6488-500.
2004: Amina El Jamali; Christian Freund; Cindy Rechner; Claus Scheidereit; Rainer Dietz; Martin W Bergmann
Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3beta.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(10):1096-8.
2004: Atsushi Ohazama; Yinling Hu; Ruth Schmidt-Ullrich; Yixue Cao; Claus Scheidereit; Michael Karin; Paul T Sharpe
A dual role for Ikk alpha in tooth development.
Developmental cell 2004;6(2):219-27.
2003: Mira Choi; Susanne Rolle; Maren Wellner; M Cristina Cardoso; Claus Scheidereit; Friedrich C Luft; Ralph Kettritz
Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis.
Blood 2003;102(6):2259-67.
2003: Stephan Mathas; Andreas Lietz; Martin Janz; Michael Hinz; Franziska Jundt; Claus Scheidereit; Kurt Bommert; Bernd Dorken
Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.
Blood 2003;102(3):1028-34.
2003: Sebastian Tegethoff; Joachim Behlke; Claus Scheidereit
Tetrameric oligomerization of IkappaB kinase gamma (IKKgamma) is obligatory for IKK complex activity and NF-kappaB activation.
Molecular and cellular biology 2003;23(6):2029-41.
2003: Benjamin Mordmüller; Daniel Krappmann; Meral Esen; Elmar Wegener; Claus Scheidereit
Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism.
EMBO reports 2003;4(1):82-7.
2002: Michael Hinz; Petra Lemke; Ioannis Anagnostopoulos; Christine Hacker; Daniel Krappmann; Stephan Mathas; Bernd Dörken; Martin Zenke; Harald Stein; Claus Scheidereit
Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.
The Journal of experimental medicine 2002;196(5):605-17.
2002: Stephan Mathas; Michael Hinz; Ioannis Anagnostopoulos; Daniel Krappmann; Andreas Lietz; Franziska Jundt; Kurt Bommert; Fatima Mechta-Grigoriou; Harald Stein; Bernd Dörken; Claus Scheidereit
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.
The EMBO journal 2002;21(15):4104-13.
2002: Franziska Jundt; Katharina Kley; Ioannis Anagnostopoulos; Kristina Schulze Pröbsting; Axel Greiner; Stephan Mathas; Claus Scheidereit; Thomas Wirth; Harald Stein; Bernd Dörken
Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease.
Blood 2002;99(8):3060-2.
2002: Nicola A Hawkes; Gabriel Otero; G Sebastiaan Winkler; Nick Marshall; Michael E Dahmus; Daniel Krappmann; Claus Scheidereit; Claire L Thomas; Giampietro Schiavo; Hediye Erdjument-Bromage; Paul Tempst; Jesper Q Svejstrup
Purification and characterization of the human elongator complex.
The Journal of biological chemistry 2002;277(4):3047-52.
2001: R Schmidt-Ullrich; T Aebischer; Jörg Hülsken; Walter Birchmeier; U Klemm; Claus Scheidereit
Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices.
Development (Cambridge, England) 2001;128(19):3843-53.
2001: Daniel Krappmann; A Patke; Vigo Heissmeyer; Claus Scheidereit
B-cell receptor- and phorbol ester-induced NF-kappaB and c-Jun N-terminal kinase activation in B cells requires novel protein kinase C's.
Molecular and cellular biology 2001;21(19):6640-50.
2001: Dominik N Muller; Vigo Heissmeyer; Ralf Dechend; Franziska Hampich; Joon-Keun Park; Anette Fiebeler; Erdenechimeg Shagdarsuren; Juergen Theuer; Marlies Elger; Bernhard Pilz; V Breu; K Schroer; Detlev Ganten; Rainer Dietz; Hermann Haller; Claus Scheidereit; Friedrich C Luft
Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2001;15(10):1822-4.
2001: Christian Wuchter; Daniel Krappmann; Zhen Cai; Velia Ruppert; Claus Scheidereit; Bernd Dörken; Wolf-Dieter Ludwig; Leonid Karawajew
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.
Leukemia 2001;15(6):921-8.
2001: Michael Hinz; P Löser; Stephan Mathas; Daniel Krappmann; Bernd Dörken; Claus Scheidereit
Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.
Blood 2001;97(9):2798-807.
2001: Susan A Slaugenhaupt; Anat Blumenfeld; Sandra P Gill; Maire Leyne; James Mull; Math P Cuajungco; CB Liebert; BP Chadwick; Maria Idelson; Luba Reznik; Christiane Robbins; Izabela Makalowska; Michael J Brownstein; Daniel Krappmann; Claus Scheidereit; Channa Maayan; Felicia B Axelrod; James Gusella
Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia.
American journal of human genetics 2001;68(3):598-605.
2001: Vigo Heissmeyer; Daniel Krappmann; Eunice N Hatada; Claus Scheidereit
Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.
Molecular and cellular biology 2001;21(4):1024-35.
2000: Daniel Krappmann; Eunice N Hatada; S Tegethoff; J Li; Anke Klippel; Klaus Giese; P A Baeuerle; Claus Scheidereit
The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component.
The Journal of biological chemistry 2000;275(38):29779-87.
2000: U Kordes; Daniel Krappmann; Vigo Heissmeyer; Wolf-Dieter Ludwig; Claus Scheidereit
Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.
Leukemia 2000;14(3):399-402.
2000: Eunice N Hatada; Daniel Krappmann; Claus Scheidereit
NF-kappaB and the innate immune response.
Current opinion in immunology 2000;12(1):52-8.
2000: Eunice N Hatada; Selina Chen-Kiang; Claus Scheidereit
Interaction and functional interference of C/EBPbeta with octamer factors in immunoglobulin gene transcription.
European journal of immunology 2000;30(1):174-84.
1999: Florian Emmerich; M Meiser; Michael Hummel; G Demel; Hans-Dieter Foss; Franziska Jundt; Stephan Mathas; Daniel Krappmann; Claus Scheidereit; Harald Stein; Bernd Dörken
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells.
Blood 1999;94(9):3129-34.
1999: Ralf Dechend; Matthias Maass; Jens Gieffers; Rainer Dietz; Claus Scheidereit; Achim Leutz; DC Gulba
Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis.
Circulation 1999;100(13):1369-73.
1999: Vigo Heissmeyer; Daniel Krappmann; FG Wulczyn; Claus Scheidereit
NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes.
The EMBO journal 1999;18(17):4766-78.
1999: Ralf Dechend; F Hirano; K Lehmann; Vigo Heissmeyer; Stéphane Ansieau; FG Wulczyn; Claus Scheidereit; Achim Leutz
The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Oncogene 1999;18(22):3316-23.
1999: Michael Hinz; Daniel Krappmann; A Eichten; A Heder; Claus Scheidereit; M Strauss
NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition.
Molecular and cellular biology 1999;19(4):2690-8.
1999: Daniel Krappmann; Florian Emmerich; U Kordes; E Scharschmidt; Bernd Dörken; Claus Scheidereit
Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.
Oncogene 1999;18(4):943-53.
1998: F Hirano; M Chung; H Tanaka; N Maruyama; I Makino; D D Moore; Claus Scheidereit
Alternative splicing variants of IkappaB beta establish differential NF-kappaB signal responsiveness in human cells.
Molecular and cellular biology 1998;18(5):2596-607.
1998: FG Wulczyn; Daniel Krappmann; Claus Scheidereit
Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.
Nucleic acids research 1998;26(7):1724-30.
1998: F Hirano; H Tanaka; Y Hirano; M Hiramoto; H Handa; I Makino; Claus Scheidereit
Functional interference of Sp1 and NF-kappaB through the same DNA binding site.
Molecular and cellular biology 1998;18(3):1266-74.
1997: Ralf C Bargou; Florian Emmerich; Daniel Krappmann; Kurt Bommert; Markus Y Mapara; W Arnold; hans-dieter royer; Edgar Grinstein; A Greiner; Claus Scheidereit; Bernd Dörken
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.
The Journal of clinical investigation 1997;100(12):2961-9.
1997: Daniel Krappmann; Claus Scheidereit
Regulation of NF-kappa B activity by I kappa B alpha and I kappa B beta stability.
Immunobiology 1997;198(1-3):3-13.
1997: M R Pelletier; Eunice N Hatada; G Scholz; Claus Scheidereit
Efficient transcription of an immunoglobulin kappa promoter requires specific sequence elements overlapping with and downstream of the transcriptional start site.
Nucleic acids research 1997;25(20):3995-4003.
1996: Daniel Krappmann; F G Wulczyn; Claus Scheidereit
Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo.
The EMBO journal 1996;15(23):6716-26.
1996: F G Wulczyn; Daniel Krappmann; Claus Scheidereit
The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation.
Journal of molecular medicine (Berlin, Germany) 1996;74(12):749-69.
1996: Ralf C Bargou; C Leng; Daniel Krappmann; Florian Emmerich; Markus Y Mapara; Kurt Bommert; hans-dieter royer; Claus Scheidereit; Bernd Dörken
High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells.
Blood 1996;87(10):4340-7.
1994: M Naumann; Claus Scheidereit
Activation of NF-kappa B in vivo is regulated by multiple phosphorylations.
The EMBO journal 1994;13(19):4597-607.
1994: S Franke; G Scholz; Claus Scheidereit
Identification of novel ubiquitous and cell type-specific factors that specifically recognize immunoglobulin heavy chain and kappa light chain promoters.
The Journal of biological chemistry 1994;269(31):20075-82.
1993: M Naumann; A Nieters; E N Hatada; Claus Scheidereit
NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B/rel-factors.
Oncogene 1993;8(8):2275-81.
1993: E N Hatada; M Naumann; Claus Scheidereit
Common structural constituents confer I kappa B activity to NF-kappa B p105 and I kappa B/MAD-3.
The EMBO journal 1993;12(7):2781-8.
1993: M Naumann; F G Wulczyn; Claus Scheidereit
The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B.
The EMBO journal 1993;12(1):213-22.
1992: F G Wulczyn; M Naumann; Claus Scheidereit
Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B.
Nature 1992;358(6387):597-9.
1992: E N Hatada; A Nieters; F G Wulczyn; M Naumann; R Meyer; Giuseppina Nucifora; Timothy W McKeithan; Claus Scheidereit
The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(6):2489-93.
1991: A Misseyanni; Claus Scheidereit; M Kalff; Miguel Beato
Neither the endogenous nor a functional steroid hormone receptor binding site transactivate the ribosomal RNA gene promoter in vitro.
The Journal of steroid biochemistry and molecular biology 1991;39(4A):409-18.
1991: U Brüggemeier; M Kalff; S Franke; Claus Scheidereit; Miguel Beato
Ubiquitous transcription factor OTF-1 mediates induction of the MMTV promoter through synergistic interaction with hormone receptors.
Cell 1991;64(3):565-72.
1991: R Meyer; E N Hatada; H P Hohmann; M Haiker; C Bartsch; U Röthlisberger; H W Lahm; E J Schlaeger; Adolphus P G M van Loon; Claus Scheidereit
Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(3):966-70.
1991: H P Hohmann; R Remy; Claus Scheidereit; Adolphus P G M van Loon
Maintenance of NF-kappa B activity is dependent on protein synthesis and the continuous presence of external stimuli.
Molecular and cellular biology 1991;11(1):259-66.